These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1716378)

  • 1. Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.
    Badylak SF; Voytik SL; Henkin J; Burke SE; Sasahara AA; Simmons A
    Thromb Res; 1991 May; 62(3):115-26. PubMed ID: 1716378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis.
    Badylak SF; Voytik SL; Henkin J; Burke S; Sasahara AA; Simmons A
    Haemostasis; 1991; 21(5):278-85. PubMed ID: 1806456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Wegner CD; Cox BF
    Thromb Haemost; 1999 Feb; 81(2):301-5. PubMed ID: 10064010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
    Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL; Chen L; Nichols WW; Johannesen M; Bregengård C; Hedner U; Saldeen TG
    J Am Coll Cardiol; 1995 Mar; 25(3):753-60. PubMed ID: 7860925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.
    Ouriel K; Kandarpa K; Schuerr DM; Hultquist M; Hodkinson G; Wallin B
    J Vasc Interv Radiol; 1999 Sep; 10(8):1083-91. PubMed ID: 10496712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
    Korninger C; Matsuo O; Suy R; Stassen JM; Collen D
    J Clin Invest; 1982 Mar; 69(3):573-80. PubMed ID: 7199539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
    Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
    Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.
    Credo RB; Burke SE
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):8S-18S. PubMed ID: 8770836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
    Gurewich V; Pannell R; Simmons-Byrd A; Sarmientos P; Liu JN; Badylak SF
    J Thromb Haemost; 2006 Jul; 4(7):1559-65. PubMed ID: 16839354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
    Kajimoto Y; Ohta T; Kuroiwa T
    Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of studies with plasminogen concentrates and proposals for further therapeutic strategies with plasminogen concentrates.
    Anderle K; Fröhlich A
    Haemostasis; 1988; 18 Suppl 1():165-75. PubMed ID: 3280422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of urokinase-induced thrombolysis in a biphasic in vitro system.
    Iga Y; Stella SR; Chandler AB
    Haemostasis; 1985; 15(3):189-97. PubMed ID: 4029755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local thrombolysis in peripheral arteries and bypass grafts.
    Pernes JM; de Almeida Augusto M; Vitoux JF; Raynaud A; Fiessinger JN; Brenot P; Fabiani JN; Murday A; Gaux JC
    J Vasc Surg; 1987 Oct; 6(4):372-8. PubMed ID: 3656585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant pro-urokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1993 Apr; 69(4):375-80. PubMed ID: 8497850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.